Publications

Selected LADRTM-related poster presentations:

Superior efficacy of novel albumin-binding auristatin E-based prodrugs compared to auristatin E in a panel of human xenograft models in mice.
AACR Annual Meeting 2018, April 14 – 18, 2018; Chicago, Illinois, USA. Abstract Number: 3703
Structure-activity relationship studies and biological evaluation of novel maytansinoids, a class of highly selective tubulin inhibitors
AACR Annual Meeting 2018, April 14 – 18, 2018; Chicago, Illinois, USA. Abstract Number: 1657
Novel albumin-binding maytansinoids inducing long-term partial and complete tumor regressions in several human cancer xenograft models in nude mice
AACR Annual Meeting 2018, April 14 – 18, 2018; Chicago, Illinois, USA. Abstract Number: 2661
LADRTM: A novel linker activated drug release technology for drug delivery
AACR Annual Meeting 2016, April 16 – 20, 2016; New Orleans, Louisiana, USA, Abstract Number: 4858

Review Articles:

Elsadek, B.; Kratz, F. Impact of albumin on drug delivery – new applications on the horizon
J. Controlled Release 2012, 157, 4–28
Kratz, F.; Elsadek, B. Clinical impact of serum proteins on drug delivery
J. Controlled Release 2012 161, 429-445
Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles
J. Controlled Release 2008, 132, 171–183
Book: Drug Delivery in Oncology – From Basic Research to Cancer Therapy
Editors: Felix Kratz, Henning Steinhagen, Peter Senter, 1st edition; Wiley-VCH: Weinheim, 2011